Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am. J. Psychiatry (1997) 154 (Suppl.) :1–39.
   Google Scholar
• PARNETTI L, SENIN U, MECOCCI P: Cognitive enhance-ment therapy for Alzheimer's disease: the way forward. Drugs (1997) 53:752–768.
   PubMedGoogle Scholar
• EAGGER SA, HARVEY RJ: Tacrine and other antiChE-drugs in dementia. Curr. Opin. Psychiatry (1995) 8:264–267.
   Google Scholar
• THAL LJ, CARTA A, DOODY R et al.: Prevention protocolsfor Alzheimer's disease: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alz. Dis. Assoc. Disord. (1997) 11 (Suppl. 3):46–49.
   Google Scholar
• LAMY PP: The role of Chns in Alzheimer's disease. CNS Drugs (1994) 1:146–165.
   Web of Science ®Google Scholar
• FARLOW MR, EVANS RM: Pharmacologic treatment of cognition in Alzheimer's Dementia. Neurology (1998) 51:36S–44S.
   Google Scholar
• JEAN JC, DAVIS RE: Cholinergic therapies for Alzheimer's disease; acetylChns of current clinical interest. Curr. Opin. Invest. Drug (1993) 2:363–377.
   Google Scholar
• EAGGER SA, HARVEY RJ: Tacrine and other antiChE-drugs in dementia. Curr. Opin. Psychiatry (1995) 8:264–267.
   Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMON PR et al.: A30-weekrandomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA (1994) 271:985–991.
   PubMed Web of Science ®Google Scholar
• DAVIS KL, THAL LJ, GAMZU ER et al.: A double-blind,placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. (1 9 9 2) 327:1253-1259.
   Google Scholar
• FARLOW M, GRACON SI, HERSHEY LA et al.: A controlledtrial of tacrine in Alzheimer's disease. JAMA (1992) 268:2523–2529.
   PubMed Web of Science ®Google Scholar
• WATKINS PB et al.: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA (1994) 271:992–998.
   PubMed Web of Science ®Google Scholar
• BEERMANN B: Side effects of long acting Chns. Acta Neurol. Scand. (1993) 149 (Suppl.) :53–54.
   Google Scholar
• HOOTEN WM, PEARLSON G: Delirium caused by tacrine and ibuprofen interaction (letter). Am. J Psychiatry (1996) 153:842.
   PubMedGoogle Scholar
• ROGER SL, FARLOW MR, DOODY RS et al.: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50:136–145.
   PubMedGoogle Scholar
• ROGERS SL, FRIEDHOFF LT: The efficacy and safety ofdonepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia (1996) 7:293–303.
   PubMedGoogle Scholar
• ENZ A, FLOERSHEIM P: Cholinesteraase inhibitors: anoverview of their mechanisms of action in Alzheimer's disease. In: Alzheimer's Disease: from Molecular Biology to Therapy. Becker R, Giaconini E (Eds.), Birkhauser, Boston (1996):211–215.
   Google Scholar
• SRAMEK JJ, ANAND R, WARDLE TS et al.:Safety/tolerability trial of SDZENA 713 in patients with probable Alzheimer's disease. Life Sci. (1996) 58:1201–1207.
   PubMed Web of Science ®Google Scholar
• ANAND R, GHARABAWI G, ENZ A: Efficacy and safety results of the early phase studies with Ex elon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev. Clin. Pract. (1996) 8:1–8.
   Google Scholar
• CUTLER NR, POLINSKY RJ, SRAMEK JJ et al.: Dose-dependent CSF acetylChEinhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol. Scand. (1998) 97:244–250.
   PubMed Web of Science ®Google Scholar
• WRIGHT CI, GEULA C, MESULAM MM: Neurological Cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles and patterns. Ann. Neurol. (1993) 34(3):373–384.
   PubMed Web of Science ®Google Scholar
• POLINSKY RJ: Clinical pharmacology of rivastigrnine: a new generation acetylChEI for the treatment of Alzheimer's disease. Clin. Ther. (1998) 20:634–647.
   PubMed Web of Science ®Google Scholar
• SPENCER CM, NOBLES: Rivastigmine. DrugsAging (1998) 13:391–411.
   Google Scholar
• NIGAWA H, TANIMKAI S, TAKEDA M, HARIGUCHI S, NISHIMURA T: Effects of SDZ ENA 713, novel acetyl-Chia, on learning of rats with basal forebrain lesions. Prog. NeuropsychopharmacoL Biol. Psychiatry (1995) 19:171–186.
   PubMedGoogle Scholar
• ENZ A, AMSTUTZ R, BOODDEKE H, GMELIN G, MALANOSKI J: Brain selective inhibition of AChE: a novel approach to therapy for Alzheimer's disease. Brain Res. (1993) 98:431–438.
   Google Scholar
• ENZ A, BODDEKE H, GRAY J, SPIEGEL R: Pharmacologicand clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylChn. Ann. NY Acad. Sci. (1991) 640:272–275.
   PubMedGoogle Scholar
• ANAND R, GHARABAWI G: Clinical development of Ex elon (ENA 713): the ADEN& programme. J. Drug Dev. Clin. Pract. (1996) 8:9–16.
   Google Scholar
• SCHRAM HG, HABUCKY K, MANCIONE LC, POLINSKY RJ, HUBERT M, GUERRET M: The effects of renal and hepatic impairment on the disposition of the acetyl-Chia SDZ ENA 713. Pharm. Res. (1996) 13:S–428.
   Google Scholar
• SMALL GW, RABINS PV, BARRY RR et al.: Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA (1997) 278:1363–1371.
   PubMed Web of Science ®Google Scholar
• FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR: 'Mini-mentalstate': a practical method for grading the cognitive state of subjects for the clinician. J. Psychiatr. Res. (1975) 12:189–198.
   PubMed Web of Science ®Google Scholar
• DEJONG R, OSTERLUND OW, ROY GW: Measurement ofquality-of-life changes in patients with Alzheimer's disease. Clin. Ther. (1989) 11:545–554.
   PubMed Web of Science ®Google Scholar
• CUTLER NR, SRAMEK JJ: The briging study: optimizing the dose for PhaseIn: Alzheimer's Disease.Therapeutic Strategies. Giacobini E, Becker R (Eds.), Birkhauser, Boston (1996) 387–391.
   Google Scholar
• HOLSBOER-TRACHSLER E, HATZINGER M, STOHLER R etal.: Effects of the novel acetylChn SDZ ENA 713 on sleep in man. Neuropsychopharmacology (1993) 8:87–92.
   Google Scholar
• STADMULLER G, BAHRO M, RIEMANN D et al.: The impact of the novel acetylcholine esterase inhibitor SDZENA 713 on sleep EFfl in Alzheimer's disease and old age depression. Neuropsychopharmacology (1994) 10:58S.
   Google Scholar
• KELLY PH, AMSTUTZ R, ENZ A: Assessment of the abuse potential of the novel Chia SDZ ENA 713 in the rhesus monkey. Nida Res. Monogr. Ser. (1993) 132:245.
   Google Scholar
• AGID Y, DUBOIS B, ANAND R et al.: Efficacy and tolerability of rivastigrnine in patients with dementia of the Alzheimer type. Curr. Ther. Res. (1998) 59:837–845.
   Web of Science ®Google Scholar
• FORETTE F, ANAND R, GHARABAWI G: A Phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose or rivastigrnine (Exelon). Eur. j Neurol. (1999) 6:423–429.
   PubMedGoogle Scholar
• COREY-BLOOM J, ANAND R, VEACH J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigrnine tar tar ate), a new acetylChn, in patients with mild-to-moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. (1998) 1:55–65.
   Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigrnine in patients with Alzheimer's disease: international randomized controlled trial. Br. Med. J. (1999) 318:633–638.
   PubMed Web of Science ®Google Scholar
• FARLOW MR, ANAND R, MESSINA J, Jr, HARTMAN R, VEACH J: a 52-week study of the efficacy of rivastig-mine in patients with mild-to-moderately severe Alzheimer's Disease. Eur. Neurol. (2000) 44:236–241.
   PubMed Web of Science ®Google Scholar
• MESSINA J: The Third Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists. Washington DC, USA (6–9 April 2000).
   Google Scholar
• SCHNEIDER LS, FARLOW MR, ANAND R: Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int. J. Geriatr. Psychopharmacol (1998) 1:S26–S34.
   Google Scholar
• HANSEN L, SALMON D, GALASKO D et al.: The Izwy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology (1990) 40:1–8.
   PubMed Web of Science ®Google Scholar
• SHERGILL S, MULLEN E, D'ATH P, KATONA C: What is the clinical prevalence of Izwy body dementia? Int. J Psychiatry (1994) 9:907–912.
   Google Scholar
• BALLARD C, HOLMES C, MCKEITH I et al.: Psychiatric morbidity in Dementia with Izwy Bodies: A prospec-tive clinical and neuropathological comparative study with Alzheimer's disease. Am. J Psychiatry (1999) 156(7):1039–1045.
   PubMed Web of Science ®Google Scholar
• MCKEITH I, DEL SER T, ANAND R et al.: Rivastigmineprovides symptomatic benefit in dementia with lewy bodies: findings from a placebo-controlled interna-tional multicenter study. Neurology (2000) 54:A450.
   Google Scholar
• KAUFER DI, CUMMINGS JL, CHRISTINE D et al.: Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. j Am. Geriatr. Soc. (1998) 46:210–215.
   PubMed Web of Science ®Google Scholar
• STEELE C, ROVNER B, CHASE GA, FOLSTEIN M: Psychi-atric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J Psychiatry (1990) 147:1049–1051.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL: Chns: A new class of psychotropic compounds. Am. J. Psychiatry (2000) 157:4–15.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, ANAND R, KOUMARAS B eta].: Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of treatment with rivastigmine. American Psychiatric Association 2000 Annual Meeting (2000).
   Google Scholar
• CUMMINGS JL, ANAND R, KOUMARAS B et al.: Rivastig-mine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a26 week trial. Neurology(2000) 54 (Suppl. 3) A468.
   Google Scholar
• JAN G, MCKEITH IG: Special workshop in dementia with Izwy bodies. Neurobiiol. Aging (1998) 19:45.
   Google Scholar
• KUMAR V, ANAND R, MESSINA J, HARTMAN R, VEACH J: An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur.J. Neurol (2000) 7(2):159–169.
   PubMedGoogle Scholar
• TANAKA K, MIZUKAWA K, OGAWA N, MORI A: Post-ischemic administration of the acetylChn ENA 713 prevents delayed neuronal death in the gerbil hippocampus. Neurochem. Res. (1995) 20:663–667.
   PubMed Web of Science ®Google Scholar
• CHEN Y, SHOAMI E, BASS R, WEINSTOCK M: Cerebro-protective effects of ENA 713, a novel acetylChn, in closed head injury in the rat. BratnRes. (1998) 784:18–24.
   PubMed Web of Science ®Google Scholar
• TANAKA K, OGAWA N, ASANUMA M et al.: Effects of the acetylChEIENA-713 on ischaemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch. Int. Pharmacodyn. (1993) 323:85–96.
   PubMedGoogle Scholar
• CUTLER NR, ANAND R, HARTMAN RD, MESSINA JC, JHEE SS: Anti-emetic therapy for Alzheimer's patients receiving the Chia SDZENA 713. Clin. Pharmacol. Ther. (1998) 63:188
   Web of Science ®Google Scholar
• JANN MW: Rivastigrnine, a New-Generation Chia forthe Treatment of Alzheimer's disease. Pharmacotherapy (2000) 20:1–11.
   PubMed Web of Science ®Google Scholar
• NORDBERG A, SVENSSON AL: Chns in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Sal (1998) 6:465–480.
   Google Scholar
• GROSSBERG GT, STAHELIN HB, MESSINA JC: lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int. J. Geriatr. Psychiatry (2000) 15:242–247.
   PubMed Web of Science ®Google Scholar
• DAVIS KL, MOHS RC, MARIN D et al.: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. Journal of the American Medical Association (1999) 281 (15):1433–1434.
   Google Scholar
• ERNST RL, HAY JW: Economic research on Alzheimer's disease: a review of literature. Alzheimer Dis. Assoc. Disord. (1997) 11:135–145.
   PubMed Web of Science ®Google Scholar
• WHITEHOUSE PJ et al.: First International Pharma-coeconomic Conference on Alzheimer's disease: Report and summary. Alzheimer Dis. Assoc. Disord. (1998) 12:266–280.
   PubMed Web of Science ®Google Scholar
• STEELE CD, STEINBERG M, MILLES G, JANN MW: Recogni-tion and management of early Alzheimer's disease. J. Clin. Outcomes Manage. (1999) 6:52–68.
   Google Scholar
• RITER RN, FRIES BE: Predictors of the placement of cognitively impaired residents on special care units. Gerontologist (1992) 32:184–190.
   PubMedGoogle Scholar
• MITTELMANN MS, FERRIS SH, STEINBERG G et al.: An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-Gerontologist (1993) 33:730–740.
   Google Scholar
• ANAND R, MESSINA J, HARTMAN R: Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int. I Geriatr. Psychopharmacol. (2000) 2:68–72.
   Google Scholar